FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OM	D /	חח		۸ / ۸
	IB 4	۱PP	ĸ.	WA

OMB Number:	3235-0287
Estimated average burder	1
hours per response:	0.5

Check this box if no longer subject to
Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PENDARVIS DAVID			2. Issuer Name and Ticker or Trading Symbol RESMED INC [ RMD ]		ionship of Reporting Person(s) all applicable) Director	s) to Issuer 10% Owner		
(Last) RESMED INC.	, , , , , , , , , , , , , , , , , , , ,		3. Date of Earliest Transaction (Month/Day/Year) 11/11/2021	X	Officer (give title below)  Chief Administrative	Other (specify below) Officer		
9001 SPECTRUM CENTER BLVD.  (Street) SAN DIEGO CA 92123		92123	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person				
(City)	(State)	(Zip)						

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Ad Disposed Of (D		4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount (A) or (D) Price		(Instr. 3 and 4)		(Instr. 4)	
ResMed Common Stock	11/11/2021		F <sup>(1)</sup>		1,549	D	\$259.47	119,502	D	
ResMed Common Stock	11/11/2021		M		983	A	\$101.64	120,485	D	
ResMed Common Stock	11/11/2021		<b>G</b> <sup>(2)</sup>	V	10,000	D	\$0	110,485(3)	D	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		Derivative		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative	9. Number of derivative Securities Beneficially Owned Following Reported		11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
ResMed Common Stock Options	\$101.64	11/11/2021		М			983	11/11/2019 <sup>(4)</sup>	11/14/2025	ResMed Common Stock	983	\$0	18,468	D	

#### **Explanation of Responses:**

- $1.\ Disposition\ to\ issuer\ for\ tax\ withholding\ on\ scheduled\ vesting\ of\ Restricted\ Stock\ Units\ granted\ 11/14/2018,\ 11/21/2019\ and\ 11/19/2020.$
- 2. Gift of shares to The San Diego Foundation, a 501(c)(3) nonprofit organization. Mr. Pendarvis has no beneficial interest, control or dispositive power over the gifted shares.
- 3. Includes 64.3996 shares of ResMed stock purchased on October 29, 2021, through the ResMed Employee Stock Purchase Plan.
- 4. Represents date options first became exercisable. Options vest  $1/3\ \mbox{per}$  year.

David Pendarvis, Chief
Administrative Officer

11/12/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.